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ABSTRACT
Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM 
progenitors are considered to contribute to disease relapse through their drug-
resistant nature. In order to improve the therapeutic efficacy for MM, we recently 
developed novel superparamagnetic nanoparticles which selectively accumulate 
in MM tumors and extirpate them by heat generated with magnetic resonance. We 
here aimed to clarify the therapeutic effects on MM cells and their progenitors by 
hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The 
treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, 
while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with 
the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell 
death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven 
survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat 
treatment almost completely eradicated “side population” fractions in RPMI8226 
and KMS-11 cells and suppressed their clonogenic capacity as determined by in vitro 
colony formation and tumorigenic capacity in SCID mice. These results collectively 
demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions 
of MM cells and enhance their susceptibility to chemotherapeutic drugs. 
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INTRODUCTION
Multiple myeloma (MM) still remains incurable 
despite the implementation of novel anti-MM agents, 
indicating the strong need for continued investigation to 
develop innovative strategies. MM-initiating cells or MM 
progenitors are considered to contribute to disease relapse 
through their drug-resistant nature, and therefore become 
among the most important targets in the treatment for 
MM [1]. MM cells not only reside in the bone marrow 
but also expand outside bone. Immature MM clonotypic 
cells or MM progenitors are rather preferentially localized 
in extraosseous niches and may eventually grow as 
extramedullary plasmacytoma [1, 2]. Extramedullary 
expansion of plasmacytoma is generally accepted to 
represent a high-risk condition with more aggressive 
features and poorer prognosis. 
Superparamagnetic iron oxide nanoparticles 
(SPIONs), contrast media for magnetic resonance imaging 
(MRI), are able to time-dependently produce heat under an 
alternating current magnetic field arbitrarily set to cover 
the contrast-enhanced tumor lesions by SPIONs, which can 
be applied to magnetic hyperthermia treatment. Therefore, 
SPIONs potentially achieve what is called “theranostics”, 
a combination of tumor imaging and targeted treatment 
for tumors [3]. We developed novel SPION nanoclusters 
coated with folic acid and polyethylene glycol via 
the thiol-ene click reaction to improve their targeting 
efficiency toward tumors [4]. In mouse plasmacytoma 
models, the SPION nanoclusters preferentially and 
selectively accumulated in plasmacytoma tumors but not 
in the bone marrow via intravenous injection, and we were 
able to diagnose tumor localization by MRI with contrast 
enhancement and generate heat to selectively kill tumor 
cells [4, 5]. Subsequently, we have synthesized magnetic 
nanoparticle clusters covered by a thermoresponsive 
polymer containing anticancer drugs of interest, which 
can target tumors and release the drugs by melting the 
polymer membrane by heat [5]. We demonstrated that 
such nanoparticle clusters were able to effectively debulk 
tumors in plasmacytoma animal models though heating 
and locally releasing an anti-cancer drug in combination. 
In the present study, we therefore aimed to determine an 
effective combination of hyperthermia with anti-MM 
agents, and clarify the impact of hyperthermia on drug-
resistant MM cells and their progenitors.
RESULTS AND DISCUSSION
Hyperthermia induces endoplasmic reticulum 
(ER) stress to cause MM cell death
The SPION nanoclusters we developed are able to 
heat within tumors without impairing non-tumorous tissues 
in plasmacytoma animal models [4, 5]. We therefore 
looked at the effects of heating at different temperatures up 
to 45°C. MM cells time-dependently underwent apoptosis 
when cultured at 43°C (Figure 1A). Hyperthermia induced 
MM cell death in a time and temperature-dependent 
manner (Figure 1B). Heat treatment at 45°C was able to 
induce substantial cell death in all MM cell lines even 
after 10 minutes. The heat treatment also reduce the 
viability of peripheral blood mononuclear cells (PBMCs) 
from normal donors, indicating impairment of normal 
cells by the heat treatment, although they seemed less 
sensitive to hyperthermia than MM cell lines at 41°C 
(Figure 1C). Therefore, because the heat treatment at 
43°C appears to impair normal cells, heating should be 
localized within tumors to selectively kill tumors but spare 
the damage in surrounding normal tissues. In this regard, 
therapeutic options to deliver tumor-targeted heating such 
as “theranostics” with SPIONs appears to be beneficial.
After the heat treatment, eIF2α was phosphorylated 
along with up-regulation of its downstream ER stress 
mediators, ATF4 and CHOP, in MM cells (Figure 2A), 
indicating induction of ER stress. We further assessed 
the induction of ER stress in MM cells by hyperthermia. 
Heat treatment at 43°C up-regulated the protein levels of 
heat shock protein70 (HSP70) and heat shock protein60 
(HSP60) along with Noxa in MM cells (Figure 2B). 
As shown in Figure 2A, the heat treatment at 43°C up-
regulated in MM cells the phosphorylation of eIF2α, 
which leads to global suppression of translation. 
Therefore, we further investigated the effects of the heat 
treatment on translation in MM cells using puromycin 
incorporation. Puromycin incorporation in neosynthesized 
proteins directly reflects the rate of mRNA translation [6]. 
The heat treatment at 43°C time-dependently reduced the 
puromycin incorporation in MM cells, which is consistent 
with the phosphorylation of eIF2α and thereby global 
suppression of translation by the heat treatment (Figure 
2C). Intriguingly, although tunicamycin, an inducer of ER 
stress, induced spliced XBP1 mRNA, the heat treatment 
did not induce it (Supplementary Figure 1A). Such acute 
intense heat treatment may perturb the enzymatic activity 
responsible for XBP1 splicing. We need to further look 
into the precise mechanism of the induction of ER stress 
in MM cells by hyperthermia.
Pim-2 is overexpressed in MM cells and regarded 
as a novel anti-apoptotic mediator for MM cells to be 
targeted [7, 8]. In parallel with the ER stress induction, 
the heat treatment reduced Pim-2 protein levels and 
Pim-2-driven survival factors, IRF4, c-Myc and Mcl-
1 (Figure 2A). To dissect the mechanisms of the Pim-2 
reduction, we first investigated the effects of the heat 
treatment on PIM2 mRNA expression in MM cells. Heat 
treatment at 39, 41 and 43°C for up to 60 minutes only 
marginally affect PIM2 mRNA expression (Figure 2D), 
although Pim-2 protein levels were apparently reduced by 
the heat treatment at 43°C for 60 minutes (Figure 2A). 
Pim-2 protein is reported to be quickly reduced in cells 
by ubiquitination-independent proteasomal degradation; 
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Figure 1: Hyperthermia induces MM cell death. (A) RPMI8226, KMS-11 and OPM-2 cells were cultured at 37 or 43°C for the 
indicated time periods. After the heat treatment, the MM cells were further cultured at 37°C for 24 hours. The cells were stained with 
annexin V-FITC and propidium iodide (PI), and then analyzed by flow cytometry. (B) MM cell lines were cultured at 37, 41, 43 or 45°C for 
10, 30 and 60 minutes. After the heat treatment, the MM cells were further cultured at 37°C for 24 hours. Cell viability was then analyzed 
by a WST-8 assay. (C) PBMCs from two normal donors were cultured at 37, 41, 43 or 45°C for 10, 30 and 60 minutes. Cell viability was 
then analyzed by a WST-8 assay. 
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Figure 2: Hyperthermia induces ER stress along with the downregulation of IRF4, Pim-2, c-Myc and Mcl-1 in MM 
cells. (A) KMS-11 and OPM-2 cells were cultured at 37 or 43°C for the indicated time periods. The cells were harvested, and the protein 
levels of phosphorylated eIF2α (p-eIF2α), ATF4, CHOP, IRF4, Pim-2, c-Myc and Mcl-1 were analyzed by Western blotting. β-actin was 
used as a protein loading control. (B) KMS-11 and OPM-2 cells were cultured at 37 or 43°C for the indicated time periods. The cells 
were harvested, and the protein levels of HSP70, HSP60 and Noxa were analyzed by Western blotting. β-actin was used as a protein 
loading control. (C) Puromycin incorporation. RPMI8226 and OPM-2 cells were treated with hyperthermia at 41 or 43°C for the indicated 
time periods. Puromycin was added at 1 µM for the last 15 minutes of the hyperthermia. The cells were harvested, and their puromycin 
incorporation was examined by Western blot analysis. β-actin was blotted as a loading control. (D) RPMI8226 and OPM-2 cells were 
treated with hyperthermia at 39 or 41 or 43°C for the indicated time periods. Then, the cells were incubated at 37°C for 6 hours. PIM2 
mRNA expression was determined by RT-PCR. GAPDH mRNA was used as an internal control. 
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thus Pim-2 protein levels in cells are mainly regulated by 
the rate of Pim-2 protein synthesis [9]. The heat treatment 
at 43°C markedly suppressed translation as indicated 
by the puromycin incorporation (Figure 2C). Therefore, 
potent suppression of translation by the heat treatment 
may at least in part cause the reduction of rapid-degrading 
Pim-2 protein in MM cells with marginally affecting its 
transcription levels.
Bortezomib or the Pim inhibitor SMI-16a 
enhances MM cell death in combination with 
hyperthermia
The proteasome inhibitor bortezomib, an ER stress 
inducer, was able to enhance the induction of CHOP and 
further suppress the protein levels of IRF4, c-Myc and 
Mcl-1 in combination with heat treatment at 43°C for 
30 minutes, although bortezomib alone showed only 
slight effects in these experimental conditions (Figure 
3A). Consistently, the heat treatment and bortezomib in 
combination cooperatively enhanced MM cell death (Figure 
3B). To elucidate the mechanism of combinatory anti-MM 
effects of hyperthermia and bortezomib, we next examined 
accumulation of ubiquitinated proteins in MM cells upon 
treatment with hyperthermia or bortezomib alone or both 
in combination.  Treatment with bortezomib substantially 
induced accumulation of ubiquitinated proteins in MM 
cells (Supplementary Figure 1B). However, ubiquitinated 
protein levels were only marginally affected in OPM-2 
MM cells after the heat treatment at 43°C for 30 minutes. 
Furthermore, the heat treatment for 60 minutes rather 
reduced ubiquitinated protein levels even under addition 
Figure 3: Hyperthermia and ER stress inducer, bortezomib or Pim inhibitor, cooperatively enhance MM cell death. 
(A) OPM-2 cells were cultured at 37 or 43°C for the indicated time periods. The cells were then cultured at 37°C for another 24 hours. 
Bortezomib (BTZ) was added at 10 nM as indicated. The protein levels of CHOP, IRF4, Pim-2, c-Myc and Mcl-1 were analyzed by 
Western blotting. (B) RPMI8226 and OPM-2 cells were cultured at 37 or 43°C for 30 minutes. The cells were further cultured at 37°C for 
48 hours. BTZ was added at 10 nM as indicated. Cell viability was analyzed by a WST-8 assay. *p < 0.05. (C) KMS-11 and OPM-2 cells 
were cultured at 37 or 43°C for 30 minutes. The cells were further cultured at 37°C for 24 hours. The Pim inhibitor SMI-16a was added at 
50 µM as indicated. The protein levels of CHOP, IRF4 and c-Myc were analyzed by Western blotting. (D) KMS-11 and OPM-2 cells were 
cultured at 37 or 43°C for 30 minutes. The cells were further cultured at 37°C for 48 hours. The Pim inhibitor SMI-16a was added at 50 µM 
as indicated. Cell viability was analyzed by WST-8 assay. *p < 0.05. HT, heat treatment.
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of bortezomib. We further investigated the accumulation of 
ubiquitinated proteins in different MM cell lines. Although 
ubiquitinated protein levels were increased in RPMI8226 
cells at 6 and 24 hours after the heat treatment at 43°C for 
30 minutes, the ubiquitinated protein levels were rather 
reduced at 24 hours after the heat treatment at 43°C for 60 
minutes (Supplementary Figure 1C, left). The heat treatment 
at 43°C did not induce the accumulation of ubiquitinated 
proteins at 6 hours, and tended to reduce ubiquitinated 
protein levels at 24 hours in KMS-11 and OPM-2 cells 
(Supplementary Figure 1C, right). These results imply 
the impairment of ubiquitination process by acute intense 
heating. It is plausible that heat treatment may perturb a 
protein synthesizing and modification process to cause 
accumulation of misfolded proteins and thereby ER stress 
without accumulation of large amounts of ubiquitinated 
proteins in MM cells. Mechanisms of the induction of ER 
stress appear to be different between heat treatment and 
bortezomib. The underlying mechanisms of the enhanced 
anti-MM effects by the combinatory treatment of acute 
intense heat treatment and proteasome inhibition seem not 
so simple, and need precise experiments, including ER-
associated degradation and E3 ligase activity after the heat 
treatment. 
Heat treatment reduced the protein levels of Pim-
2, which may make MM cells more susceptible to Pim 
inhibition. Indeed, the Pim inhibitor SMI-16a almost 
completely eliminated Pim-2-driven survival mediators, 
IRF4 and c-Myc, in MM cells, which were already reduced 
by the heat treatment (Figure 3C). The combinatory 
treatment of heating with the Pim inhibition cooperatively 
increased MM cell death (Figure 3D). 
Hyperthermia minimizes “side population” and 
suppresses colony formation in MM cells
The SP is considered to be a drug resistant fraction 
containing cancer stem cells [10]. SP fractions were 
reported to be distinctly detected in the MM cell lines 
RPMI8226 and KMS-11 [11, 12]. Importantly, heat 
treatment at 43 and 45°C for 30 minutes markedly reduced 
the sizes of SP fractions in these MM cell lines although 
sizable non-SP fractions remained (Figure 4A), suggesting 
that SP cells can be targeted with heating. The heat 
treatment also suppressed colony formation of these MM 
cell lines in a temperature-dependent manner (Figure 4B). 
To further clarify the effects of hyperthermia on stemness 
or self-renewal capacity of MM cells, we next examined 
the effects of heat treatment on the tumorigenic capacity of 
MM cells using xenograft models. Luciferase-transfected 
RPMI8226 cells were treated with or without heat 
treatment at 43°C for 30 minutes, and then transplanted 
subcutaneously in SCID mice. The transplantation of MM 
cells without the heat treatment formed tumors in all the 
mice; however, no tumors formed in mice with inoculation 
of the heat-treated MM cells (Figure 4C). These results 
suggest that tumorigenic MM cells with a self-renewal 
capacity are susceptible to hyperthermia.
In summary, heat treatment is demonstrated 
to effectively enhance ER stress possibly through 
enhanced protein misfolding by heat, thereby inducing 
phosphorylation of eIF2α, along with the up-regulation of 
ATF4 and CHOP, to cause apoptosis in MM cells and their 
progenitors with stemness or self-renewing capacity. The 
enhanced ER stress may subsequently suppress translation 
of critical pro-survival mediators such as Pim-2, IRF4, 
c-Myc and Mcl-1, leading to further potentiation of MM 
cell death. 
Hyperthermia was demonstrated in the present 
study to be able to effectively target SP fractions as well 
as MM progenitors with self-renewal capacity. MM 
cancer stem cells have been proposed to be responsible 
for drug resistance and relapse, although they have not 
been properly defined yet in MM [13]. Cancer stem cells 
are generally accepted to be dormant and resistant to a 
variety of chemotherapeutic drugs, and thereby cause 
an eventual relapse [14, 15]. Previous studies suggested 
that SP fractions may contain MM cancer stem cells [12, 
16]. Given the existence of MM cancer stem cells in SP 
fractions in MM cells, hyperthermia may become a good 
therapeutic option to effectively target MM cancer stem 
cells. 
We are currently developing new versions of 
mesoporous nanoparticles containing SPIONs, which 
can store anticancer drugs and selectively release them 
in tumor lesions after targeting tumors when heat is 
generated by magnetic resonance. In the present study, we 
demonstrated that the combination with the proteasome 
inhibitor bortezomib or the Pim inhibitor SMI-16a is able 
to potentiate heat-induced MM cell killing. Therefore, 
the above mesoporous nanoparticles carrying proteasome 
inhibitors or Pim inhibitors warrant further study, 
especially in the setting of drug-resistant extramedullary 
plasmacytomas. The strategy of “theranostics” with 
drug-containing and heat-generating nanoparticles can 
be also applied to malignant lymphoma such as NK 
cell lymphoma, and various solid cancers which remain 
resistant to conventional treatment modalities.
MATERIALS AND METHODS
Reagents
The following reagents were purchased from the 
indicated manufacturers: SMI-16a and mouse monoclonal 
antibody against Noxa from Calbiochem (Darmstadt, 
Germany); rabbit polyclonal anti-antibodies against human 
IRF4, bortezomib and mouse monoclonal antibody against 
C/EBP-homologous protein (CHOP), phosphorylated 
eukaryotic Initiation Factor 2α (p-eIF2α) and activating 
transcription factor 4 (ATF4) from from Cell Signaling 
Technology (Beverly, MA); Pim-2 and c-Myc from Abcam 
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(Cambridge, UK); HSP70 from Biolegend (San Diego, CA); 
HSP60 from StressMarq Biosciences Inc.(Victoria, Canada); 
Mcl-1 from Medical and Biotechnological Laboratories 
(Nagoya, Japan); tunicamycin, puromycin and β-actin from 
Sigma (Saint Louis, MO); anti-puromycin antibody from 
Kerafast, Inc (Boston, MA) ; and anti-ubiquitin antibody 
was obtained from Millipore (Darmstadt, Germany).
Cells and cultures 
The human MM cell lines, RPMI8226, KMS-11 
were obtained from the American Type Culture Collection 
(Rockville, MD, USA). TSPC-1 and OPC were established 
in our laboratory [17]. OPM-2 was purchased from the 
German Collection of Microorganisms and Cell Cultures 
Figure 4: Hyperthermia impairs clonogenic MM cells. (A) RPMI8226 and KMS-11 cells were cultured at 37, 43 or 45°C for 30 
minutes. The cells were subsequently cultured at 37°C for 24 hours, and % distributions of SP fractions were determined by flow cytometry. 
(B) RPMI8226 and KMS-11 cells were cultured at 37, 41, 43 and 45°C for 30 minutes, and then subjected to methylcellulose assay. After 
culturing for 14 days, colony numbers were counted. (C) pGL4-transfected RPMI8226 were cultured at 37 or 43°C for 30 minutes, and 
then the MM cells were subcutaneously transplanted into SCID mice. The MM tumors were visualized at 6 weeks after the inoculation. 
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(Braunschweig, Germany). MM.1S was kindly provided 
by Dr. Steven Rosen (Northwestern University, Chicago, 
IL, USA). PBMCs were isolated from normal subjects 
as described previously [17]. All procedures involving 
human specimens were performed with written informed 
consent according to the Declaration of Helsinki and using 
a protocol approved by the Institutional Review Board for 
human protection.
Cell viability and apoptosis assays
Culture tubes with MM cell lines were tightly 
closed and immersed in a water bath at 41, 43 or 45°C 
for 10, 30 and 60 minutes. After the heat treatment, the 
MM cells were washed and incubated at 37°C 5%CO2 
for 24 hours. Viable cell numbers were measured by cell 
proliferation assay using 2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
(WST-8; Kishida Chemical, Osaka, Japan). To assess 
apoptotic cells, cells were stained with an annexinV-FITC 
and propidium iodide labeling kit (MEBCYTO Apoptosis 
Kit; MBL, Nagano, Japan) according to the manufacturer’s 
instruction, and analyzed by flow cytometry. 
Side population (SP) analysis 
SP fractions were analyzed as described previously 
[18, 19]. Briefly, cells were incubated at 1.0×106 /ml with 
5 μg/ml Hoechst 33342 (Sigma) for 90 minutes at 37°C 
in phosphate-buffered saline containing 3% fetal bovine 
serum, in the presence or absence of 100 mM verapamil 
(Sigma). After the incubation, the cells were washed and 
propidium iodide (1 mg/ml) was added to dead cells. SP 
fractions were analyzed with a flow cytometer (Beckman 
Coulter, Tokyo, Japan). 
Colony assay
After heat treatment, MM cells were plated 
out in triplicates at 1 × 104 cells per dish into H4034 
methylcellulose medium (Stem Cell Technologies), and 
cultured for 14 days. The numbers of colonies with > 40 
cells were then counted under an inverted microscope.
Western blot analysis 
Cells were collected and lysed in lysis buffer (Cell 
Signaling, Beverly, MA) supplemented with 1 mM 
phenylmethylsulfonyl fluoride and protease inhibitor 
cocktail solution (Sigma). The cell lysates were subjected 
to SDS-PAGE on a 10% polyacrylamide gel, and then 
transferred to polyvinylidene difluoride membranes 
(Millpore, Billerica, MA). The membranes were blocked 
with 5% non-fat dry milk in TBS with 0.01% Tween 
20 for 1 hour at room temperature and incubated for 16 
hours at 4°C with the primary antibodies. After washing, 
a secondary horseradish peroxidase-conjugated antibody 
was added and the membranes were developed using 
the enhanced chemiluminescence plus Western blotting 
detection system (American Biosciences, Piscataway, NJ). 
RT-PCR
Total RNA was extracted from cells using 
TRIZOL reagent (Gibco BRL, Rockville, MD). For 
reverse transcription-polymerase chain reaction (RT-
PCR), 2 µg of total RNA was reverse-transcribed with 
Superscript II (Gibco) in a 20-µL reaction solution. 
One tenth of the RT-PCR products were used for 
subsequent PCR analysis with 24–30 cycles of 95°C 
for 30 seconds, 58°C for 30 seconds and 72°C for 30 
seconds. The following primers were used: The primers 
used for RT-PCR were as follows: human Pim-2 sense 
5ʹ-GGTAAGGGATTGAGGATC-3ʹ and anti-sense 
5ʹ-TGGGGTATTGGAAGGAAAG-3ʹ; human XBP1 sense 
5ʹ-CCTTGTAGTTGAGAACCAGG-3ʹ and antisense 
5ʹ-GGGGCTTGGTATATATGTGG-3ʹ; human GAPDH 
sense 5ʹ-TGTCTTCACCACCATGGAGAAGG-3ʹ and 
anti-sense 5ʹ-GTGGATGCAGGGATGATGTTCTG-3ʹ.
Establishment of luciferase-transfected 
RPMI8226 cells
Transfection of pGL4 luc (Promega) into 
RPMI8226 cells was performed using Lipofectamine LTX 
(Invitorogen) reagents according to the manufacturer’s 
protocol. A total of 2.5 μg of pGL4-luc in 200 μl Opti-
MEM was mixed with 6 μl Lipofectamine LTX reagent 
for 15 minutes at an ambient temperature. The DNA-
LTX complex was then added to 6-well culture dishes 
containing 106 cells. The medium was replaced at 16 
hours after transfection, and the cells were subcultured 
in a medium containing G418 Geneticin at a final 
concentration of 500 μg/ml for 2 weeks. The medium was 
replenished every 3 days. The drug-resistant colonies were 
selected.
Animal model
Severe combined immunodeficiency (SCID) mice 
(Charles River, Tokyo, Japan) were injected with 100 µl anti-
asialo GM1 antiserum (Wako, Osaka, Japan) 1 day before 
tumor inoculation to eradicate residual natural killer cells. 
Luciferase-transfected RPMI8226 cells were treated with or 
without heat at 43°C for 30 minutes, and then the MM cells 
were transplanted subcutaneously in SCID mice. Six weeks 
after the inoculation, the tumorigenic capacity was evaluated 
by IVIS imaging system (SPI Summit Pharmaceuticals 
International, Tokyo, Japan). Animal experiments were 
conducted under the regulation and permission of the 
Animal Care and Use Committee of Tokushima University, 
Tokushima, Japan (toku-dobutsu 11083).
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Statistical analysis
Data were expressed as mean ± standard deviation. 
The differences in the means between groups were 
compared using a one-way analysis of variance (ANOVA) 
with Scheffe’s post hoc tests. P ≤ 0.05 was considered as a 
significant difference. All statistics were performed using 
the Statistical Package for Social Sciences (SPSS 13.0 for 
Windows; Chicago, IL).
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